Heart Outcomes Prevention and Evaluation 4

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1438 participants.

Also called NCT01826019

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose health services research
Phase
Phase 4
Enrolled
  • 1,438 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01826019
Other papers using this trial's data
  • A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial Lancet (London, England), 2019-10-05 DOI, PubMed 31488369

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada, Colombia, Malaysia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01826019. Randomized; no masking; primary purpose health services research. Start 2014-08 (actual); primary completion 2019-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Heart Outcomes Prevention and Evaluation 4
Acronym
HOPE-4
Condition
Hypertension
Condition
Cardiovascular Disease
Intervention (Other)
Intervention
Intervention (Other)
Usual Care
Lead sponsor
Hamilton Health Sciences Corporation (class: other)
Collaborator
Population Health Research Institute (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)
Collaborator
Grand Challenges Canada (class: other)
Collaborator
Global Alliance for Chronic Diseases (GACD) (class: other)

Record details

Record id
cardio:ct-nct01826019
Content hash
9b14b0b1d343f8b21c8051b6bb7bd776345be250fc4a8906aaec39becf7ccb31